The ALS Association, a U.S.-based nonprofit whose mission is to help find a cure for amyotrophic lateral sclerosis (ALS), has issued a statement strongly opposing plans for cuts in National Institutes of Health (NIH) funding, saying any such reductions would obstruct progress in ALS research. The organization also…

Having access to results from prognostic tests — including neurofilament light chain (NfL) and the ALS Functional Rating Scale-Revised (ALSFRS-R) — is informational, personally relevant, and relevant to research for people with amyotrophic lateral sclerosis (ALS), a study suggests. The perceived burden related to receiving the tests results was…

This year’s Atlanta Night of Hope Gala will showcase how patient April Byars has been navigating life since her ALS diagnosis. The gala, which is hosted by the Muscular Dystrophy Association (MDA) to raise funds for amyotrophic lateral sclerosis (ALS) research is now in its 18th year.

Fifteen nonprofit organizations across the U.S. formed a new ALS group, ALS United, to better address the needs of people living with amyotrophic lateral sclerosis (ALS) and drive advances in research toward better treatment options or a cure. The groups said they plan to pool resources to support…

Neighborhood disadvantage, or living in regions with poorer socioeconomic conditions, is significantly associated with shorter survival time among people with amyotrophic lateral sclerosis (ALS), according to a new Michigan-based study. For those living in neighborhoods considered to be among the top 10% of the most disadvantaged, survival was reduced…

Oral therapy IFB-088 (icerguastat) was safe and significantly slowed disease progression in certain people with amyotrophic lateral sclerosis (ALS), according to new data from a Phase 2 clinical trial. “We are very encouraged by the results we observed with IFB-088,” Pierre Miniou, CEO of IFB-088’s developer Inflectis Bioscience,…

A clinical trial that will test a noninvasive, nerve-modulating device called MyoRegulator — designed to slow disease progression in people with amyotrophic lateral sclerosis (ALS) — has been cleared to start patient enrollment in the U.S. That green light, from an Institutional Review Board, will allow Pathmaker…

People with amyotrophic lateral sclerosis (ALS) who choose invasive ventilation to help with breathing less frequently require opioids to manage their symptoms compared with ALS patients who remain on noninvasive ventilation or have no ventilatory support at all, according to a new study by researchers in Japan. Opioid use…

Repeated traumatic brain injuries (TBIs), which happen when the brain is damaged by external impacts such as a fall or a car accident, can accelerate the onset and progression of amyotrophic lateral sclerosis (ALS) associated with mutations in the SOD1 gene, a new mouse study suggests. The effects of…

uniQure is planning to start enrolling patients in a second dose group as part of a clinical trial testing AMT-162, its one-time gene therapy for amyotrophic lateral sclerosis (ALS) associated with mutations in the SOD1 gene. The open-label Phase 1/2 study, called EPISOD1 (NCT06100276) is intended to…